Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;7(4):337-42.
doi: 10.2174/157015909790031166.

Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies

Saiju Jacob  1 , Yusuf A Rajabally
Affiliations

Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies

Saiju Jacob et al. Curr Neuropharmacol. 2009 Dec.

Abstract

Intravenous immunoglobulins (IVIg) have been shown in a number of trials, to be an effective treatment for the three main types of inflammatory neuropathies: Guillain-Barré Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). IVIg is thought to exert its immunomodulatory effects by affecting several components of the immune system including B-cells, T-cells, macrophages, complement, cytokines and cellular adhesion molecules. This article reviews the published evidence and the principal postulated mechanisms of action of intravenous immunoglobulins with special emphasis on inflammatory neuropathies.

Keywords: Chronic inflammatory demyelinating polyneuropathy; Guillain Barre syndrome; Intravenous immunoglobulins; inflammatory neuropathy; mechanisms of action; multifocal motor neuropathy..

PubMed Disclaimer

References

    1. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;2:809–810. - PubMed
    1. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997;349:225–230. - PubMed
    1. Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994;84:2136–2143. - PubMed
    1. Azulay JP, Blin O, Pouget J, Boucraut J, Bille-Turc F, Carles G, Serratrice G. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994;44:429–432. - PubMed
    1. Basta M, Illa I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis. J. Neuroimmunol. 1996;71:227–229. - PubMed

LinkOut - more resources